SCHEMBL1974014

SCHEMBL1974014

CC(C)(C)c1cccc(NC(=O)O)c1CC=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
POLB P06746 3/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 1/20 0.36
LPAR1 Q92633 1/20 0.36
NLRP3 Q96P20 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX2 P34913 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77844 0.79 ALDH1A1 (0.41) ALDH1A1POLBGAATHRBALOX12
SCHEMBL2093266 0.79 ALDH1A1 (0.58) ALDH1A1POLBGAATHRBALOX12
SCHEMBL7026726 0.79 CA2 (0.43) ALDH1A1POLBGAATHRBALOX12
SCHEMBL26661715 0.76 TAS2R14 (0.45) ALDH1A1POLBGAATHRBALOX12
SCHEMBL7022661 0.76 GABRA1 (0.46) ALDH1A1GAAALOX12NLRP3SMN1; SMN2
SCHEMBL2085952 0.73 TAS2R14 (0.43) ALDH1A1POLBGAATHRBALOX12
SCHEMBL26695392 0.70 ALDH1A1 (0.46) ALDH1A1POLBGAATHRBALOX12
SCHEMBL15397564 0.69 MAPT (0.44) ALDH1A1POLBGAAKMT2AL3MBTL1
SCHEMBL8980065 0.69 ALDH1A1 (0.51) ALDH1A1POLBGAATHRBALOX12
SCHEMBL2963432 0.68 CYP2C19 (0.56) ALDH1A1POLBGAATHRBALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B ALDH1A1 3648/4885POLB 3271/4885GAA 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.